Upstream Bio Inc Revenue Growth Rates (UPB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Upstream Bio Inc   (NASDAQ: UPB)
 

UPB's Revenue Growth by Quarter and Year

Upstream Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UPB/growth
https://api.csimarket.com/api/v1/companies/UPB/fundamentals
https://api.csimarket.com/api/v1/companies/UPB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
UPB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.40
2nd Quarter June 0.77
1st Quarter March 1.03
FY 2.20





UPB Revenue third quarter 2026 Y/Y Growth Comment
Upstream Bio Inc reported fall in Revenue in the third quarter 2026 by -41.91% to $ 0.40 millions, from the same quarter in 2025.
The drop in the third quarter 2026 Upstream Bio Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 7.57%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 68 other companies have achieved higher Revenue growth. While Upstream Bio Inc ' s Revenue drop of -41.91% ranks overall at the positon no. 927 in the third quarter 2026.


UPB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -41.91 %
2nd Quarter June -18.09 %
1st Quarter March 80.7 %
FY   -

Financial Statements
Upstream Bio Inc 's third quarter 2026 Revenue $ 0.40 millions UPB's Income Statement
Upstream Bio Inc 's third quarter 2025 Revenue $ 0.68 millions Quarterly UPB's Income Statement


UPB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -48.7 %
2nd Quarter June -25.24 %
1st Quarter March 53.73 %
FY (Year on Year)   -


Back to UPB Growth rate Comparisons >> Back to UPB Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #183
Overall #927

Revenue Y/Y Growth Statistics
High Average Low
44.69 % 7.57 % -22.86 %
(Mar 31 2026)   (Jun 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #69
Healthcare Sector #183
Overall #927
Revenue Y/Y Growth Statistics
High Average Low
44.69 % 7.57 % -22.86 %
(Mar 31 2026)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Upstream Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
183.25 % 16.13 % -63.62 %
(Dec 31 2023)  


UPB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Upstream Bio Inc disclosed fall in Revenue from the second quarter by -48.7% to $ 0.40 millions, from $ 0.77 millions achived in the previous reporting period.

But that's not important problem, as Upstream Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 161 other companies have achieved higher Revenue quarter on quarter growth. While Upstream Bio Inc 's Revenue growth quarter on quarter, overall rank is 3402.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #162
Healthcare Sector #471
Overall #3402
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #162
Healthcare Sector #471
Overall #3402
Revenue Q/Q Growth Statistics
High Average Low
183.25 % 16.13 % -63.62 %
(Dec 31 2023)  


UPB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Upstream Bio Inc disclosed fall in Revenue from the second quarter by -48.7% to $ 0.40 millions, from $ 0.77 millions achived in the previous reporting period.

But that's not important problem, as Upstream Bio Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 161 other companies have achieved higher Revenue quarter on quarter growth. While Upstream Bio Inc 's Revenue growth quarter on quarter, overall rank is 3402.


Upstream Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 2.87
Y / Y Revenue Growth (TTM) 2.54 %
Year on Year Revenue Growth Overall Ranking # 3448
Seqeuential Revenue Change (TTM) -9.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 927


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Upstream Bio Inc 's cumulative twelve months Revenue were $ 3 millions, company would post below average annual Revenue growth of -9.12% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Upstream Bio Inc 's Revenue growth from the 0.77% growth in Jun 30 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1405 to 3448.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 460
Overall # 3448

Revenue TTM Y/Y Growth Statistics
High Average Low
44.69 %
 7.57 %
-22.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 183
S&P 500 # 927
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Upstream Bio Inc 's cumulative twelve months Revenue were $ 3 millions, company would post below average annual Revenue growth of -22.86% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Upstream Bio Inc 's Revenue growth from the 0.77% growth in Jun 30 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1405 to 3448.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 69
Healthcare Sector # 460
Overall # 3448

Revenue TTM Y/Y Growth Statistics
High Average Low
44.69 %
7.57 %
-22.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 183
S&P 500 # 927




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
UPB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Nuwellis Inc -0.23%$ -0.226 millions
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions


About Upstream Bio Inc Revenue Growth Rates (UPB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Upstream Bio Inc (CIK 2022626).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-454422
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Upstream Bio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.